• Pan Cancer

  Participated · Grant · Dec 2025

  Pan Cancer T is a Rotterdam-based biotech spin-out from Erasmus MC (founded in 2020) that engineers TCR-T cell therapies for hard-to-treat solid cancers. Its platform pairs broadly expressed tumour targets with proprietary technologies designed to enhance T-cell durability, aiming to improve efficacy against solid tumours. The lead program, PCT1:CO-STIM, is being prepared for a first-in-human trial in women with triple-negative breast cancer. Additional pipeline programs address malignancies of the skin, colorectum, stomach, oesophagus, ovary and uterus. To date the company has secured roughly €21 million in capital, comprising €2 million in grants, an Innovation Credit loan and multiple equity financings. The latest infusion strengthens its cash position to advance pre-clinical work through the clinic while expanding its broader solid-tumour pipeline. Existing investors continue to back the firm alongside non-dilutive government support, reflecting confidence in its differentiated approach.

• Orbital Eye

  Participated · Equity · Dec 2023

  Orbital Eye BV, founded in 2012 and based in Delft, provides satellite-based monitoring and inspection services intended to replace traditional helicopter-based aerial inspections. The company automatically processes large volumes of radar and optical satellite images daily across thousands of square kilometers, using detection and filter algorithms to distinguish relevant changes and upload alerts for inspectors, asset managers, and HSE officers. Its services are offered via a Data Subscription model that requires no upfront customer investments. As a member of the S[&]T group, Orbital Eye has direct access to over 100 specialists in earth observation, big data processing, and software engineering. The company announced it secured €2M in new funding led by S[&]T Ventures, with support from the Netherlands Enterprise Agency (RVO) and the Ministerie van Economische Zaken en Klimaat via the InnovatieKrediet instrument. Management says the capital will be used to scale the technology, further exploit AI, and automate its satellite-based monitoring solutions to serve customers of any network size while maintaining monitoring performance.

• BIOeCON

  Led · Equity · Apr 2011

  BIOeCON develops non-edible biomass conversion technologies and has created three proprietary processes. The company is advancing a fuel cell concept called BiCEPS, developed with Eindhoven University of Technology, to convert cellulosic biomass directly into electricity. It raised an additional €1m comprising an investment from existing shareholders plus a grant from the Dutch Ministry of Economic Affairs to design and build a BiCEPS prototype. The prototype will be built by a team led by BIOeCON’s business development director, Dr. Hans Heinerman. Previously BIOeCON formed a 2007 Houston-based joint venture, KiOR, to commercialize Biomass Catalytic Cracking (BCC) — funded by Khosla Ventures and now in demonstration with a plant under construction in Mississippi. In 2009 the company entered a joint development agreement with PETROBRAS to scale BiCHEM and established an international research group led by Prof. emeritus Jacob Moulijn at the High Tech Campus in Eindhoven to demonstrate BiCHEM at pilot scale.

No current team members are available.